MetaStat, Inc. announced it has received California, Florida, Pennsylvania, and Rhode Island state licensure for its next-generation digital pathology laboratory in Boston, Massachusetts. These state certifications follow receipt of CLIA certification from U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) that now allow MetaStat to accept clinical samples from 48 states. Results from a clinical study led by ECOG-ACRIN Cancer Research Group, presented at the 39th San Antonio Breast Cancer Symposium (SABCS) in December 2016, found the MetaSite Breast™ test was able to identify patients at greater risk of distant cancer metastasis who had low Oncotype DX Recurrence Score results. Results from a Kaiser Permanente Cohort Study demonstrated MetaSite Breast™ score was a statically significant predictor of distant metastasis and a binary cutpoint was able to discriminate high and low risk patient groups.